COMMUNIQUÉS West-GlobeNewswire

Unum Therapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 13, 2019 at 8:00 A.M. ET
06/05/2019
CAMBRIDGE, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer using its novel [...]
Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)
06/05/2019
- Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs - - Enrollment Progressing in Pivotal CONNECT-FX Trial of Zygel in FXS, with Data Expected in the Second Half of [...]
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
06/05/2019
- Partial responses in 4 out of 5 synovial sarcoma patients treated with ~10 billion cells, with tumor shrinkage in nearly all assessed synovial sarcoma patients in the ADP-A2M4 pilot study - - Initiating SPEARHEAD-1 [...]
Recro Pharma to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 10, 2019
06/05/2019
Conference Call and Webcast Scheduled for Friday, May 10, 2019 at 8:00 a.m. ET MALVERN, Pa., May 06, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report first quarter financial [...]
One World Pharma Enters into First Colombian Seed Sale Agreement
06/05/2019
First Sale Signals One World’s Entry into Monetization Phase LAS VEGAS, NV, May 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – One World Phama Inc. (OTC: OWPC), a fully licensed cannabis cultivator and manufacturer [...]
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
06/05/2019
Topline results now anticipated in 2H 2019 Trial enriched with only patients with history of inadequate response to prior migraine treatments Trial compares AXS-07 to placebo and active comparator Trial being conducted [...]
Protalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate Update
06/05/2019
CARMIEL, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]
Pluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry
06/05/2019
Company is exploring the opportunity to utilize its proprietary 3-D cell culturing technology in the manufacturing of cannabinoid-producing cells HAIFA, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics [...]
Arrayit Corporation Retains Top Credentialing Company to Accelerate Allergy Testing Services Reimbursement from Major Healthcare Payors
06/05/2019
Sunnyvale, May 06, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, announces that it has retained a seasoned healthcare credentialing organization to [...]
Zealand Pharma hosts conference call on May 16 at 4 pm CET (10 am EST) to present first quarter results for 2019
06/05/2019
Press Release – No. 09 / 2019 Zealand Pharma hosts conference call on May 16 at 4 pm CET (10 am EST) to present first quarter results for 2019 Copenhagen, May 6, 2019 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR [...]
Share buy-back week 18/2019
06/05/2019
Announcement 6 May 2019 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling up [...]
Ordinary and Extraordinary General Meeting of May 24, 2019 - Procedures for Obtaining Preparatory Documents for the General Meeting
06/05/2019
Montrouge, France, May 3, 2019 Ordinary and Extraordinary General Meeting of May 24, 2019 Procedures for Obtaining Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – [...]
Assemblée Générale Mixte du 24 mai 2019 - Modalités de mise à disposition des documents préparatoires à l’Assemblée
06/05/2019
Montrouge, France, le 3 mai (22h30 CEST) 2019 Assemblée Générale Mixte du 24 mai 2019 Modalités de mise à disposition des documents préparatoires à l’Assemblée DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – [...]
LIDDS: Liproca® Depot open label extension study indicates longer treatment intervals
06/05/2019
Preliminary data from a voluntary open label extension (OLE) study indicates that the time to re-treatment with Liproca® Depot in prostate cancer patients is potentially longer than anticipated. This information comes [...]
Reminder: C-RAD Web Presentation Interim Report Q1 2019
06/05/2019
Presentation of the report for the first quarter of the fiscal year 2019: Date: Wednesday May 8, 2019 / kl. 13:00 Venue: Online Presentation Topic: C-RAD Interim Report Q1 2019 Procedure: Please register online through [...]
Herantis Pharma publishes newsletter for March-April
06/05/2019
Herantis Pharma publishes newsletter for March-April Herantis Pharma Plc Press release 6 May 2019 at 9:00 am Herantis Pharma plc (“Herantis”) has published its newsletter for March-April. The newsletter is also attached [...]
ERYTECH proposes the appointment of Dr. Jean-Paul Kress as Chairman of the Board of Directors
06/05/2019
LYON, France, May 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug [...]
ERYTECH propose la nomination du Dr. Jean-Paul Kress au poste de Président du Conseil d’administration
06/05/2019
LYON, France, 06 mai 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), société biopharmaceutique en phase clinique développant des thérapies innovantes par encapsulation de substances [...]
Dr. Thomas Walters Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019
06/05/2019
Press Release Dr. Thomas Walters Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019 Enrollment rate now at 90% Key Opinion Leader endorsement of the potential for NCX 470 in [...]

Pages